Menu Search
Equities

Regenxbio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RB0:FRA

Regenxbio Inc

Actions
  • Price (EUR)7.80
  • Today's Change-0.80 / -9.30%
  • Shares traded200.00
  • 1 Year change-1.27%
  • Beta1.0588
Data delayed at least 15 minutes, as of Feb 10 2026 07:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

  • Revenue in USD (TTM)161.32m
  • Net income in USD-177.92m
  • Incorporated2008
  • Employees353.00
  • Location
    Regenxbio Inc9804 Medical Center DriveROCKVILLE 20850United StatesUSA
  • Phone+1 (240) 552-8181
  • Fax+1 (302) 655-5049
  • Websitehttps://regenxbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.